Matheus Oliveira Do Nascimento
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matheus Oliveira Do Nascimento has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- André Luis Menezes Carvalho
Postgraduate Program in Pharmaceutical Sciences, Dermopharmacy Laboratory, Pharmaceutical Technology Center, Federal University of Piauí, Teresina 64049-550, PI, Brazil
2 shared publications - Allan Kayk Sales Meneses
Postgraduate Program in Chemistry, Organic Geochemistry Laboratory, Department of Chemistry, Federal University of Piauí, Teresina 64049-550, PI, Brazil
1 shared publication - Amanda Mara Teles
Universidade Estadual do Maranhão, Brasil
1 shared publication - Arlan Silva Freitas
Doutor em Ciência Animal Instituto Federal de Educação Ciência e Tecnologia Maranhão -Campus São Luís-Monte Castelo Endereço São Luis Maranhão Brasil
1 shared publication - Carla Verônica Rodarte de Moura
Postgraduate Program in Chemistry, Biodiesel and Materials Laboratory, Department of Chemistry, Federal University of Piauí, Teresina 64049-550, PI, Brazil
1 shared publication - Carolina Borges Cordeiro
Universidade Federal do Maranhão, Brazil
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1229
Co-Delivery of Fluconazole and Riparin B Using Nanostructured Lipid Carriers: A Quality-by-Design Approach for Enhanced Antifungal Activity
Background/Objectives: The increasing incidence of invasive fungal infections and the emergence of antifungal resistance have limited the effectiveness of conventional therapies against Candida spp. This study aimed to develop and optimize nanostructured lipid carriers (NLCs) containing fluconazole (FLC) and Riparin B (RIP) using a systematic Quality-by-Design (QbD) approach. Methods: The optimized NLCs were characterized by particle size, polydispersity index (PDI), zeta potential, DSC, and FTIR analyses. Molecular docking was used as a complementary exploratory approach to investigate possible interactions of RIP with representative components of the lipid matrix and with fungal resistance-associated proteins. Release profiles and antifungal activity against Candida spp. were also evaluated. Results: The optimized NLCs exhibited a mean particle size of 144.9 ± 2.25 nm, PDI of 0.153 ± 0.03, and zeta potential of −27.8 ± 1.81 mV. DSC and FTIR analyses supported the structural organization of the lipid matrix and the formation of an imperfect crystalline network, providing structural defects favorable for the incorporation of the active compounds. RIP exhibited more favorable predicted interactions than FLC within the specific lipid configuration evaluated, although these docking scores should not be interpreted as direct thermodynamic measurements of drug–lipid affinity or as quantitative predictors of encapsulation efficiency. Docking analyses with MdR1, CdR1, and CdR2 identified possible interactions of RIP with these resistance-associated proteins, providing a structural hypothesis that may contribute to understanding the potentiation of FLC activity. However, these computational results do not establish direct efflux-pump inhibition. Release profiles followed distinct kinetic regimes, consistent with matrix relaxation for RIP and Fickian diffusion for FLC. Although RIP alone did not exhibit relevant antifungal activity, its association with FLC potentiated FLC activity against Candida spp., while incorporation of the combination into NLCs produced a further enhancement, significantly reducing the minimum inhibitory concentration. Conclusions: These findings indicate that the optimized NLC platform can enhance the antifungal performance of the FLC–RIP combination and provide a formulation framework for further investigation of this co-delivery strategy.
- 28 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1229
Open AccessCo-Delivery of Fluconazole and Riparin B Using Nanostructured Lipid Carriers: A Quality-by-Design Approach for Enhanced Antifungal Activity
Background/Objectives: The increasing incidence of invasive fungal infections and the emergence of antifungal resistance have limited the effectiveness of conventional therapies against Candida spp. This study aimed to develop and optimize nanostructured lipid carriers (NLCs) containing fluconazole (FLC) and Riparin B (RIP) using a systematic Quality-by-Design (QbD) approach. Methods: The optimized NLCs were characterized by particle size, polydispersity index (PDI), zeta potential, DSC, and FTIR analyses. Molecular docking was used as a complementary exploratory approach to investigate possible interactions of RIP with representative components of the lipid matrix and with fungal resistance-associated proteins. Release profiles and antifungal activity against Candida spp. were also evaluated. Results: The optimized NLCs exhibited a mean particle size of 144.9 ± 2.25 nm, PDI of 0.153 ± 0.03, and zeta potential of −27.8 ± 1.81 mV. DSC and FTIR analyses supported the structural organization of the lipid matrix and the formation of an imperfect crystalline network, providing structural defects favorable for the incorporation of the active compounds. RIP exhibited more favorable predicted interactions than FLC within the specific lipid configuration evaluated, although these docking scores should not be interpreted as direct thermodynamic measurements of drug–lipid affinity or as quantitative predictors of encapsulation efficiency. Docking analyses with MdR1, CdR1, and CdR2 identified possible interactions of RIP with these resistance-associated proteins, providing a structural hypothesis that may contribute to understanding the potentiation of FLC activity. However, these computational results do not establish direct efflux-pump inhibition. Release profiles followed distinct kinetic regimes, consistent with matrix relaxation for RIP and Fickian diffusion for FLC. Although RIP alone did not exhibit relevant antifungal activity, its association with FLC potentiated FLC activity against Candida spp., while incorporation of the combination into NLCs produced a further enhancement, significantly reducing the minimum inhibitory concentration. Conclusions: These findings indicate that the optimized NLC platform can enhance the antifungal performance of the FLC–RIP combination and provide a formulation framework for further investigation of this co-delivery strategy.
- Open Access
- 1 February 2024
- Published by Brazilian Journals in OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA
- Vol. 22 (2) , e3334
Pharmacological application of microemulsion formulated with rhizopus sp extract
Fungi have been recognized as a great source of bioactive metabolites with great medical and pharmaceutical applicability. The objective of this work was to produce a fungal extract from Rhizopus spp and identify the secondary metabolites obtained, followed by preparation of a microemulsion formulated with Rhizopus sp extract; characterizing its antioxidant and antimicrobial activity. Among the metabolites obtained, sorbitol, linoleic acid, oleic acid, palmitic acid, and stearic acid stand out. The formulated microemulsion proved to be an effective pharmacological presentation in preserving the metabolites obtained from the fungal extract, and also potentiating in relation to the extract, when comparing the antioxidant activity and antimicrobial action.
- 1 February 2024
- Published by Brazilian Journals in OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA
- Vol. 22 (2) , e3334
Open AccessPharmacological application of microemulsion formulated with rhizopus sp extract
Fungi have been recognized as a great source of bioactive metabolites with great medical and pharmaceutical applicability. The objective of this work was to produce a fungal extract from Rhizopus spp and identify the secondary metabolites obtained, followed by preparation of a microemulsion formulated with Rhizopus sp extract; characterizing its antioxidant and antimicrobial activity. Among the metabolites obtained, sorbitol, linoleic acid, oleic acid, palmitic acid, and stearic acid stand out. The formulated microemulsion proved to be an effective pharmacological presentation in preserving the metabolites obtained from the fungal extract, and also potentiating in relation to the extract, when comparing the antioxidant activity and antimicrobial action.